T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.

ABSTRACT: Patients with B-cell malignancies receiving CD19-targeted chimeric antigen receptor (CAR) T-cell therapy may experience treatment failure due to various mechanisms. One significant factor is the host's immune response against the CAR-T product, mainly triggered by the immunogenicity of non-human sequences present in the CAR construct. In the CART19-BE-01 clinical trial (NCT03144583, ClinicalTrials.gov), patients with relapsed/refractory B-cell malignancies received treatment with varnimcabtagene autoleucel (ARI-0001 cells), a CD19-targeted autologous CAR-T product. During follow-up, both humoral and cellular immune responses were assessed against the extracellular domain of ARI-0001 cells, which was derived from the murine monoclonal antibody A3B1. Here, we report the case of a patient wit

SUBMITTER: Bartolo-Ibars A 

PROVIDER: S-EPMC12458724 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature